fingolimod hydrochloride has been researched along with Lymphoma, Mantle-Cell in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andritsos, L; Baskar, S; Byrd, JC; Chen, CS; Chiang, CL; Flynn, J; Frissora, FW; Jones, J; Lee, LJ; Lee, RJ; Mani, R; Mao, Y; Mo, X; Muthusamy, N; Phelps, MA; Rader, C; Wang, J; Wu, Y; Yan, R; Yu, B; Yu, L; Zhao, Y | 1 |
| Baiocchi, R; Baskar, S; Byrd, JC; Chen, CS; Chiang, CL; Frissora, FW; Klisovic, R; Lee, LJ; Lee, RJ; Mani, R; Mo, X; Muthusamy, N; Phelps, MA; Rader, C; Yan, R | 1 |
| Alinari, L; Baiocchi, RA; Byrd, JC; Chen, CS; Dalton, JT; Lapalombella, R; Lin, T; Liu, Q; Mani, R; Muthusamy, N; Yan, F; Zhang, X | 1 |
| Alinari, L; Baiocchi, RA; Blum, KA; Byrd, JC; Chen, CS; Earl, CT; Goldenberg, DM; Huynh, L; Mahoney, E; Mani, R; Mao, Y; Muthusamy, N; Patton, J; Praetorius-Ibba, M; Quinion, C; Towns, WH; Yu, B; Zhang, X | 1 |
| Alinari, L; Baiocchi, RA; Praetorius-Ibba, M | 1 |
5 other study(ies) available for fingolimod hydrochloride and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Lymphoma, Mantle-Cell; Mice; Mice, Transgenic; Nanoparticles; Oligonucleotide Array Sequence Analysis; Phosphorylation; Propylene Glycols; Protein Kinase C; Receptor Tyrosine Kinase-like Orphan Receptors; Sphingosine; Treatment Outcome | 2015 |
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Differentiation, B-Lymphocyte; Antigens, Neoplasm; Cytotoxins; Drug Delivery Systems; Fingolimod Hydrochloride; Histocompatibility Antigens Class II; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Propylene Glycols; Receptor Tyrosine Kinase-like Orphan Receptors; Sphingosine; Xenograft Model Antitumor Assays | 2015 |
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin D1; Female; Fingolimod Hydrochloride; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Propylene Glycols; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sphingosine; Xenograft Model Antitumor Assays | 2010 |
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class II; Humans; Immunoblotting; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Lysosomes; Mice; Mice, SCID; Microscopy, Confocal; Microtubule-Associated Proteins; Propylene Glycols; Protein Transport; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Fingolimod Hydrochloride; Humans; Lymphoma, Mantle-Cell; Mice; Neoplasm Proteins; Phosphorylation; Propylene Glycols; Sphingosine; Treatment Outcome | 2012 |